Randomized Controlled Trial
Copyright ©The Author(s) 2020.
World J Gastroenterol. Dec 21, 2020; 26(47): 7568-7583
Published online Dec 21, 2020. doi: 10.3748/wjg.v26.i47.7568
Table 1 Baseline characteristics of the patients

Intervention (n = 738)
Control (n = 746)
P value
Demographic variables
Age (yr), mean (SD)59.1 (16.2)59.9 (16.0)0.307
Male sex, n (%)347 (47)363 (48.7)0.527
Foreign nationality, n (%)94 (12.7)102 (13.7)0.594
Advanced studies, n (%)148 (20.1)149 (20.0)0.834
Language barrier, n (%)67 (9.1)53 (7.1)0.163
Clinical variables
BMI, mean (SD)26.7 (4.7)26.9 (4.6)0.657
Diabetes mellitus, n (%)126 (17.1)125 (16.8)0.871
Abdominal/pelvic surgery, n (%)287 (38.9)292 (39.1)0.920
Constipation, n (%)148 (20.1)161 (21.6)0.469
Anxiety-depression syndrome, n (%)253 (34.3)253 (33.9)0.881
Disabled condition, n (%)29 (3.9)33 (4.4)0.634
Charlson index, mean (SD)0.5 (0.9)0.5 (0.9)0.322
ASA classification III-IV, n (%)84 (11.4)100 (13.4)0.237
High comorbidity burden, n (%)33 (4.5)42 (5.6)0.308
Antiaggregants, n (%)
Aspirin73 (9.9)72(9.7)0.798
Clopidogrel6 (0.8)9 (1.2)
Dual APA1 (0.1)2 (0.3)
VKA, n (%)24 (3.3)28 (3.8)0.600
DOAC, n (%)
Rivaroxaban4 (0.5)4 (0.5)0.735
Apixaban8 (1.1)(1.2)
Dabigatran3 (0.4)5 (0.7)
Endoscopic variables
Previous endoscopy, n (%)335 (45.4)323 (49.1)0.417
Previous non-attendance, n (%)77 (10.4)86 (11.5)0.500
Referring physician, n (%)
Primary care668 (90.5)684 (91.7)0.128
Gastroenterologist70 (9.5)62 (8.3)
Indication, n (%)
Surveillance211 (28.6)197 (26.4)0.620
Diagnostic456 (61.8)(63.3)
Family history of CRC71 (9.6)77 (10.3)
Waiting time (d), mean (SD)60.7 (56.6)59.5 (60.9)0.701
Afternoon timetable, n (%)467 (63.3)746 (67.3)0.104
Laxative, n (%)
MCSP102 (15.1)80 (12.5)0.372
PEG + ascorbate, 2 L158 (23.4)3.2)
PEG, 4 L416 (61.5)411 (64.3)
Previous cleansing problems, n (%)37 (5)44 (5.9)0.453